Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Bernstein has downgraded Amgen (AMGN) to Market Perform from Outperform, arguing that 2026 could be a “waiting year” for the pharma giant and its stock will remain within 15% of its $335 per share ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

SaveHealth reports on cholesterol medications, detailing common types like statins, their effects, and safety considerations for treatment.

The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite.

Check out some of the medications affected by drugmakers raising prices on life-saving medications this year, as well as some ...

The deals tout significant discounts for people who pay out of pocket for certain medications. But most people with insurance ...

Investing in dividend stocks, which can help boost returns through dividend reinvestment, is particularly good, as they have ...

Amgen has announced a deal with the US government that will lower the company’s prescription drug costs for US patients while reinforcing its commitment to US innovation.

A new government-run discount medicine website is set to launch this month. It's called TrumpRx: A direct-to-consumer drug ...

The drug manufacturing giant is expected to announce its fiscal fourth-quarter earnings for 2025 in the near term. Ahead of ...